A New Federal Pathway for Homeopathy:
Senate Bill 4692 Introduced to Protect American Access to Homeopathic Medicine

Senators Tommy Tuberville (R-AL) and Mike Lee (R-UT) Introduce the Homeopathic Drug Product Safety, Quality, and Transparency Act

Overview

On June 4, 2026, U.S. Senator Tommy Tuberville (R-AL) introduced Senate Bill 4692, formally titled the Homeopathic Drug Product Safety, Quality, and Transparency Act. The bill is co-sponsored by Senator Mike Lee (R-UT) and has been referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP). It is the Senate companion to H.R. 7050, introduced earlier in 2026 by Representative Pete Sessions in the House.

For the millions of Americans who rely on homeopathic medicines as part of their personal healthcare, and for the practitioners and manufacturers who serve them, S.4692 represents the most significant legislative effort in decades to restore regulatory clarity, protect consumer access, and recognize homeopathy as a distinct and legitimate category of medicine under federal law.

Why This Bill Matters: The Regulatory Background

The U.S. Food and Drug Administration (FDA) first recognized homeopathic medicines under the Federal Food, Drug, and Cosmetic Act of 1938, and regulated them as a distinct class of products for the next eighty years. In 2019, however, the FDA abruptly withdrew its longstanding guidance (Compliance Policy Guide 400.400), leaving the homeopathic industry — and the consumers who rely on it — in a state of regulatory uncertainty. A subsequent 2022 FDA guidance imposed significant new restrictions on the lawful sale of homeopathic drug products, treating them under a framework designed for conventional pharmaceuticals.

The result has been years of confusion: homeopathic medicines that have been safely used for generations have faced the threat of being pulled from the market not because of any safety concerns, but because they were being evaluated against criteria designed for a fundamentally different category of drugs.

S.4692 is intended to correct that mismatch.

Key Provisions of S.4692

According to the official summary released by Senator Lee’s office, the Homeopathic Drug Product Safety, Quality, and Transparency Act would:

• Federally recognize homeopathic drug products as distinct from other pharmaceutical products, requiring their own independent regulatory framework.
• Establish a standard statutory definition of “homeopathic drug product” and clarify that such products are not “new drugs” under the Federal Food, Drug, and Cosmetic Act.
• Exempt homeopathic drug products from the traditional premarket approval process under Section 505 of the Federal Food, Drug, and Cosmetic Act — the process designed for conventional pharmaceuticals.
• Create a separate regulatory pathway for the FDA to oversee safety and quality standards tailored specifically to homeopathy.
• Exempt finished homeopathic drug products from required laboratory tests that measure the strength of each active ingredient — testing that is impractical and inappropriate for homeopathic dilutions.
• Permit homeopathy-appropriate labeling, including descriptions and dosage units consistent with traditional homeopathic practice, and clarify that claims made in compliance with the Act shall not be deemed false advertising.
• Establish a Homeopathic Drug Product Advisory Committee to consult with the Secretary of Health and Human Services on safety, quality, labeling, and regulatory approaches. The committee will include representatives from both consumer and practitioner backgrounds.
• Require the FDA to issue final Current Good Manufacturing Practice (CGMP) regulations tailored to homeopathic products within three years of enactment.
• Deem any non-homeopathic drug or supplement that uses the word “homeopathy” in its labeling as misbranded, protecting consumers from deceptive marketing.
• Apply federal serious-adverse-event reporting standards for nonprescription drugs to homeopathic drug products.
• Clarify that homeopathic drug products are not classified as biosimilars.
• Withdraw the FDA’s restrictive 2022 guidance on homeopathic drug products.
• Preserve state authority over the practice of homeopathy, leaving state homeopathic licensure and practice laws untouched.

Taken together, these provisions would replace today’s regulatory limbo with a clear, predictable, and homeopathy-appropriate federal framework.

What the Sponsors Are Saying

In introducing the bill, Senator Tuberville emphasized that he has long been a supporter of homeopathic medicine and believes Americans deserve access to safe, affordable, natural alternatives. He noted that the FDA should have a meaningful pathway to review and approve homeopathic remedies rather than leaving them in regulatory uncertainty.

Senator Lee framed the legislation as a matter of healthcare freedom, arguing that the current federal framework — built around conventional pharmaceuticals — is poorly suited to evaluate homeopathic products. He said the bill responds to thousands of American families who have asked Washington for a better approach.

Broad Coalition of Endorsements

S.4692 has been endorsed by a wide coalition of consumer, health-freedom, and industry organizations, including:

• Americans for Homeopathy Choice Action
• MAHA Action (Make America Healthy Again Action)
• The CPAC Foundation
• The National Health Federation
• The Health Freedom Defense Fund
• The Natural Products Association

These organizations represent millions of American consumers, practitioners, and businesses who collectively view the bill as a long-overdue step toward securing access to homeopathic medicine for future generations.

What This Means for Homeopathy Supporters

For supporters of homeopathic medicine, S.4692 is more than a piece of legislation — it is a federal affirmation that homeopathy occupies a unique and legitimate place in the American healthcare landscape. The bill recognizes a simple reality: homeopathic medicines have been safely used in the United States for nearly two centuries and continue to be relied upon by millions of consumers and licensed health practitioners today.

If enacted, the Homeopathic Drug Product Safety, Quality, and Transparency Act would:

• Protect continued consumer access to the homeopathic medicines families depend on.
• Provide regulatory certainty for manufacturers, retailers, and practitioners.
• Ensure appropriate safety and quality standards designed specifically for homeopathic products.
• Stop the misuse of the term “homeopathy” in mislabeled mainstream products.
• Restore the original 1938 framework’s recognition of homeopathy as a distinct category of medicine.

Current Status and Next Steps

S.4692 was introduced on June 4, 2026, read twice, and referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP). Its House companion, H.R. 7050, is currently before the House Committee on Energy and Commerce.

The Homeopathic Medicine PAC will continue to monitor the bill’s progress, advocate for its advancement, and provide our supporters with timely updates and opportunities to engage their elected representatives.

We encourage all Americans who value access to homeopathic medicine to contact their U.S. Senators and ask them to support S.4692, the Homeopathic Drug Product Safety, Quality, and Transparency Act.

Sources and Further Reading

• Bill page: S.4692 — 119th Congress (2025-2026)
• Cosponsors: Congress.gov cosponsor list
• Senator Lee’s press release (June 5, 2026): lee.senate.gov
• House companion bill: H.R. 7050 — Homeopathic Drug Product Safety, Quality, and Transparency Act

The Homeopathic Medicine PAC is committed to protecting and advancing Americans’ access to safe, effective homeopathic medicine through policy advocacy, education, and civic engagement.